Evolution of uterine adenomyosis volume during and after GnRH antagonist (linzagolix) treatment: lessons for further clinical trials

Donnez, Jacques;Donnez, Olivier;Dolmans, Marie-Madeleine
(2023) Fertility and sterility — Vol. 120, n° 5, p. 1071-1073 (2023)

Files

1-s20-S0015028223006994-main.pdf
  • Open Access
  • Adobe PDF
  • 511.77 KB
Download

Details

Authors
Abstract
(en) OBJECTIVE : Uterine adenomyosis is described as an estrogen-dependent benign uterine disease characterized by infiltration of the myometrium by endometrial glands to a depth of >2.5 mm. Oral gonadotropin-releasing hormone (GnRH) antagonists have been reported to offer a promising new potential treatment option, allowing dose-dependent control of estradiol (E2) levels and being characterized by the absence of a flare-up effect and rapid reversibility. [...]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Donnez, J., Donnez, O., & Dolmans, M.-M. (2023). Evolution of uterine adenomyosis volume during and after GnRH antagonist (linzagolix) treatment: lessons for further clinical trials. Fertility and sterility, 120(5), 1071-1073. https://doi.org/10.1016/j.fertnstert.2023.07.012 (Original work published 2023)